top of page
Gynecologic Cancer Surveillance: Best Practices & Updates with Dr. Ritu Salani, Dr. Mona Guo, Dr. Marcia Ciccone on the BackTable OBGYN Podcast
00:00 / 01:04

Save your progress. Continue watching on the BackTable app.

BackTable Women's Health

Episode # 132  •  01 Sept 2026

Gynecologic Cancer Surveillance: Best Practices & Updates

Does catching cancer earlier with surveillance always translate to better outcomes for gynecologic cancer patients? On this episode of BackTable Women’s Health, hosts Dr. Mona Guo and Dr. Marcia Ciccone interview Dr. Ritu Salani, Professor of OBGYN at UCLA and lead author of the updated SGO surveillance clinical practice statements. They discuss how post–curative-intent surveillance has evolved amid limited prospective evidence, review the latest guidelines, and highlight the real-world challenges of balancing early detection, patient safety, and cost.

Timestamps

00:00 - Introduction
03:05 - Evolving Guidelines and Consensus
10:02 - Lead-Time Bias and Cost Considerations
12:05 - Maintenance Therapy and Surveillance Nuances
14:44 - Ovarian and Endometrial Cancer: Imaging vs Exam
20:24 - Key Takeaways from the TOTEM Trial
24:04 - Future Tools, Lifestyle Counseling, and Shared Care
27:21 - Cytology, HPV Testing, and Post-Radiation Surveillance
31:13 - Hormone Therapy Considerations
34:37 - ctDNA and MRD Testing
37:39 - Emerging Technologies and Limitations
43:22 - Rapid Fire Takeaways
45:33 - Closing Thoughts

Resources

You may also like

See more of the content that's relevant to your practice.

More about this episode

The conversation explores practice variability, the lack of clear survival benefits from routine imaging and tumor markers, and the risks of cascade testing and lead-time bias. Dr. Salani reviews the TOTEM trial data for endometrial cancer, the importance of symptom review and pelvic exams (especially for lower genital tract cancers), and the reduced role of cytology, even in cervical cancer after radiation. They also discuss shared-care models, lifestyle counseling, hormone therapy considerations, and the promise and limitations of emerging technologies like ctDNA and MRD testing during maintenance therapy.

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page